PUBLIC COMPANY
save$MLYSMineralys Therapeutics, Inc.
$MLYS15.33+0.59%Radnor, PA, USupdated 10d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
- phase2A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
- phase2A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
- phase3Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
- phase2Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
- phase2Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
🐶 Hiring Signal
News
- FDA approves AstraZeneca’s new kind of hypertension drugBaxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.biopharma_dive · 6mo ago
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that